At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 54 enrolled
Drug / intervention
Niclosamide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Single and Multiple Ascending Dose Study to Assess the Safety and Pharmacokinetics of Niclosamide in Healthy Adults
In Brief
A Phase 1 clinical trial evaluating Niclosamide and Placebo for Healthy. Completed, enrolled 54 participants across 1 site.
Detailed Summary
A single and multiple ascending dose study of ANA001 in healthy adults to assess the safety and pharmacokinetics
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
Enrollment StartNov 2020
First PostedJan 2021
Primary CompletionOct 2021
Study CompletionOct 2022
TodayJul 2026
First PostedJan 12, 2021
Enrollment StartNov 17, 2020
Primary CompletionOct 13, 2021
Study CompletionOct 28, 2022
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 5.5 years ago
Interventions
Niclosamidedrug
Niclosamide is an antihelmintic with in-vitro antiviral activity
Placebodrug
Matching hydroxypropylmethylcellulose HPMC capsules with no active ingredients